Synthesis and Nanoformulation Core

合成和纳米制剂核心

• 批准号: 8554598
• 负责人: SHANTU G AMIN
• 金额: $ 15.06万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-10 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8554598
• 关键词: ADME Study; Analytical Chemistry; Biological; Ceramides; Chemical Agents; Chemicals; Drug Formulations; Encapsulated; Individual; Liposomes; Metabolism; Molecular; N-caproylsphingosine; Radiolabeled; SKI gene; Sphingolipids; Tamoxifen; Techniques; analog; base; experience; galactosylgalactosylglucosylceramidase; inhibitor/antagonist; kinase inhibitor; member; nanoformulation; nanoliposome; new therapeutic target; novel; programs; radiotracer; research study; sphingosine kinase

The Synthesis and Nanoformulation Core (SNC) will supply ceramide analogs, acid ceramidase (AC) inhibitors, sphingosine kinase inhibitors, and tamoxifen metabolites essential to the members of this Program Project. In addition, the Core will also provide liposomal formulations of C6-ceramide derivatives, acid ceramidase inhibitors, sphingosine kinase inhibitor SKI-178, and tamoxifen metabolites to the Projects 1, 2, 3, and 4, respectively. Furthermore, the Core will also synthesize [^H] AC inhibitors and [^

合成和纳米制剂核心（SNC）将提供神经酰胺类似物、酸性神经酰胺酶（AC） 抑制剂、鞘氨醇激酶抑制剂和本计划成员必需的他莫昔芬代谢物 项目此外，核心还将提供C6-神经酰胺衍生物的脂质体制剂，酸 神经酰胺酶抑制剂、鞘氨醇激酶抑制剂SKI-178和他莫昔芬代谢物与项目1，2， 3和4，分别。此外，核心还将合成[^H] AC抑制剂和[^H] AC抑制剂。